Daré Bioscience (NASDAQ:DARE) Share Price Crosses Below Two Hundred Day Moving Average of $4.51

Daré Bioscience, Inc. (NASDAQ:DARE)’s stock price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $4.51 and traded as low as $3.30. Daré Bioscience shares last traded at $3.31, with a volume of 15,215 shares traded.

Analyst Ratings Changes

Separately, Maxim Group reiterated a “hold” rating on shares of Daré Bioscience in a research note on Wednesday, August 14th.

Daré Bioscience Stock Performance

The firm has a market cap of $28.30 million, a price-to-earnings ratio of -0.86 and a beta of 1.39. The business has a fifty day moving average of $3.45 and a two-hundred day moving average of $4.51.

Daré Bioscience (NASDAQ:DARE) last posted its earnings results on Monday, August 12th. The biotechnology company reported $1.52 earnings per share for the quarter, beating the consensus estimate of ($0.57) by $2.09. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.60 million. On average, equities research analysts forecast that Daré Bioscience, Inc. will post -0.27 earnings per share for the current year.

Institutional Investors Weigh In On Daré Bioscience

An institutional investor recently raised its position in Daré Bioscience stock. Renaissance Technologies LLC raised its holdings in Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 778,700 shares of the biotechnology company’s stock after purchasing an additional 15,800 shares during the period. Renaissance Technologies LLC owned 9.25% of Daré Bioscience worth $262,000 at the end of the most recent reporting period. 6.70% of the stock is owned by institutional investors.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.